Needham & Company LLC Reaffirms “Buy” Rating for Autolus Therapeutics (NASDAQ:AUTL)

Needham & Company LLC reissued their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research note released on Thursday,Benzinga reports. Needham & Company LLC currently has a $10.00 price target on the stock.

Several other analysts have also commented on the stock. Wells Fargo & Company lowered their price objective on shares of Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a research report on Friday, March 21st. Truist Financial lowered their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Autolus Therapeutics currently has a consensus rating of “Buy” and an average target price of $9.32.

Autolus Therapeutics Price Performance

AUTL opened at $2.15 on Thursday. The company’s 50-day moving average is $1.53 and its 200 day moving average is $1.96. Autolus Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $5.00. The firm has a market capitalization of $572.20 million, a P/E ratio of -1.78 and a beta of 1.76.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The business had revenue of $8.98 million for the quarter, compared to analyst estimates of $1.59 million. On average, equities research analysts expect that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

Several hedge funds have recently added to or reduced their stakes in AUTL. Jane Street Group LLC purchased a new position in shares of Autolus Therapeutics in the fourth quarter worth about $26,000. Barclays PLC increased its stake in shares of Autolus Therapeutics by 1,094.3% in the fourth quarter. Barclays PLC now owns 11,859 shares of the company’s stock worth $28,000 after purchasing an additional 10,866 shares in the last quarter. Invesco Ltd. increased its stake in shares of Autolus Therapeutics by 53.3% in the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after purchasing an additional 11,381 shares in the last quarter. Daiwa Securities Group Inc. increased its stake in shares of Autolus Therapeutics by 55.5% in the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company’s stock worth $56,000 after purchasing an additional 8,479 shares in the last quarter. Finally, Virtus ETF Advisers LLC increased its stake in shares of Autolus Therapeutics by 29.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company’s stock worth $62,000 after purchasing an additional 6,081 shares in the last quarter. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.